DK3313874T3 - Maskering af kimære antigen-receptor t-celler til tumorspecifik aktivering - Google Patents
Maskering af kimære antigen-receptor t-celler til tumorspecifik aktivering Download PDFInfo
- Publication number
- DK3313874T3 DK3313874T3 DK16815514.1T DK16815514T DK3313874T3 DK 3313874 T3 DK3313874 T3 DK 3313874T3 DK 16815514 T DK16815514 T DK 16815514T DK 3313874 T3 DK3313874 T3 DK 3313874T3
- Authority
- DK
- Denmark
- Prior art keywords
- chimary
- masking
- tumor
- cells
- antigen receptor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70517—CD8
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70521—CD28, CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3015—Breast
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3023—Lung
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3038—Kidney, bladder
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3053—Skin, nerves, brain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562185398P | 2015-06-26 | 2015-06-26 | |
PCT/US2016/039670 WO2016210447A1 (en) | 2015-06-26 | 2016-06-27 | Masking chimeric antigen receptor t cells for tumor-specific activation |
Publications (1)
Publication Number | Publication Date |
---|---|
DK3313874T3 true DK3313874T3 (da) | 2021-05-03 |
Family
ID=57586556
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK16815514.1T DK3313874T3 (da) | 2015-06-26 | 2016-06-27 | Maskering af kimære antigen-receptor t-celler til tumorspecifik aktivering |
Country Status (7)
Country | Link |
---|---|
US (1) | US10822419B2 (da) |
EP (1) | EP3313874B1 (da) |
JP (1) | JP2018518972A (da) |
CN (1) | CN107709356A (da) |
CA (1) | CA2986604A1 (da) |
DK (1) | DK3313874T3 (da) |
WO (1) | WO2016210447A1 (da) |
Families Citing this family (82)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108129554A (zh) | 2010-08-10 | 2018-06-08 | 洛桑聚合联合学院 | 红细胞结合性治疗剂 |
US9517257B2 (en) | 2010-08-10 | 2016-12-13 | Ecole Polytechnique Federale De Lausanne (Epfl) | Erythrocyte-binding therapeutics |
US9850296B2 (en) | 2010-08-10 | 2017-12-26 | Ecole Polytechnique Federale De Lausanne (Epfl) | Erythrocyte-binding therapeutics |
CA3131724A1 (en) | 2013-12-17 | 2015-06-25 | Genentech, Inc. | Anti-cd3 antibodies and methods of use |
SG11201606761RA (en) | 2014-02-21 | 2016-09-29 | Ecole Polytecnique Federale De Lausanne Epfl Epfl Tto | Glycotargeting therapeutics |
US10046056B2 (en) | 2014-02-21 | 2018-08-14 | École Polytechnique Fédérale De Lausanne (Epfl) | Glycotargeting therapeutics |
US10946079B2 (en) | 2014-02-21 | 2021-03-16 | Ecole Polytechnique Federale De Lausanne | Glycotargeting therapeutics |
US10953101B2 (en) | 2014-02-21 | 2021-03-23 | École Polytechnique Fédérale De Lausanne (Epfl) | Glycotargeting therapeutics |
MX2017014908A (es) | 2015-05-21 | 2018-08-15 | Harpoon Therapeutics Inc | Proteinas de union triespecificas y metodos de uso. |
US10822419B2 (en) | 2015-06-26 | 2020-11-03 | University Of Southern California | Masking chimeric antigen receptor T cells for tumor-specific activation |
CN106519037B (zh) * | 2015-09-11 | 2019-07-23 | 科济生物医药(上海)有限公司 | 可活化的嵌合受体 |
US20190112380A1 (en) * | 2016-03-29 | 2019-04-18 | University Of Southern California | Chimeric antigen receptors targeting cancer |
WO2017192536A1 (en) | 2016-05-02 | 2017-11-09 | University Of Kansas | Eliminating mhc restriction from the t cell receptor as a strategy for immunotherapy |
JP7042467B2 (ja) | 2016-05-20 | 2022-03-28 | ハープーン セラピューティクス,インク. | 単鎖可変フラグメントcd3結合タンパク質 |
US11623958B2 (en) | 2016-05-20 | 2023-04-11 | Harpoon Therapeutics, Inc. | Single chain variable fragment CD3 binding proteins |
US10100106B2 (en) | 2016-05-20 | 2018-10-16 | Harpoon Therapeutics, Inc. | Single domain serum albumin binding protein |
JP7160482B2 (ja) | 2016-09-02 | 2022-10-25 | レンティジェン・テクノロジー・インコーポレイテッド | Duocarを用いてがんを処置するための組成物および方法 |
CN109923128A (zh) | 2016-11-15 | 2019-06-21 | 基因泰克公司 | 用于用抗cd20/抗cd3双特异性抗体进行治疗的给药 |
US10844134B2 (en) | 2016-11-23 | 2020-11-24 | Harpoon Therapeutics, Inc. | PSMA targeting trispecific proteins and methods of use |
CA3044659A1 (en) | 2016-11-23 | 2018-05-31 | Harpoon Therapeutics, Inc. | Prostate specific membrane antigen binding protein |
WO2018148224A1 (en) * | 2017-02-07 | 2018-08-16 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Phospholipid ether (ple) car t cell tumor targeting (ctct) agents |
CN110637033A (zh) * | 2017-02-22 | 2019-12-31 | 艾丽塔生物治疗剂公司 | 用于治疗癌症的组合物和方法 |
US11535668B2 (en) | 2017-02-28 | 2022-12-27 | Harpoon Therapeutics, Inc. | Inducible monovalent antigen binding protein |
US20200115461A1 (en) * | 2017-05-03 | 2020-04-16 | Harpoon Therapeutics, Inc. | Compositions and methods for adoptive cell therapies |
WO2018206791A1 (en) * | 2017-05-12 | 2018-11-15 | Cellectis | Protease based switch chimeric antigen receptors for safer cell immunotherapy |
KR20200026810A (ko) | 2017-05-12 | 2020-03-11 | 하푼 테라퓨틱스, 인크. | Msln 표적화 삼중 특이적 단백질 및 사용 방법 |
EP3606950A1 (en) * | 2017-05-12 | 2020-02-12 | Cellectis | Protease based switch chimeric antigen receptors for safer cell immunotherapy |
JP7090347B2 (ja) | 2017-05-12 | 2022-06-24 | ハープーン セラピューティクス,インク. | メソテリン結合タンパク質 |
WO2018232176A1 (en) | 2017-06-16 | 2018-12-20 | The University Of Chicago | Compositions and methods for inducing immune tolerance |
CN111263640A (zh) * | 2017-09-27 | 2020-06-09 | 俄亥俄州创新基金会 | 组织因子靶向car-nk和car-t细胞疗法 |
JP7084990B2 (ja) | 2017-10-13 | 2022-06-15 | ハープーン セラピューティクス,インク. | 三重特異性タンパク質と使用方法 |
BR112020007249B1 (pt) | 2017-10-13 | 2022-11-22 | Harpoon Therapeutics, Inc | Roteína de ligação a antígeno de maturação de célula b, proteína de ligação multiespecífica e uso das referidas proteínas |
SG11202003543WA (en) | 2017-10-18 | 2020-05-28 | Intrexon Corp | Polypeptide compositions comprising spacers |
CN109776671B (zh) * | 2017-11-14 | 2022-05-27 | 杭州康万达医药科技有限公司 | 分离的t细胞受体、其修饰的细胞、编码核酸、表达载体、制备方法、药物组合物和应用 |
WO2019111249A1 (en) * | 2017-12-05 | 2019-06-13 | The Medical Research Infrastructure And Health Services Fund Of The Tel Aviv Medical Center | T-cells comprising anti-cd38 and anti-cd138 chimeric antigen receptors and uses thereof |
WO2019113385A1 (en) * | 2017-12-07 | 2019-06-13 | Janux Therapeutics, Inc. | Modified t cell receptors |
US20210189367A1 (en) * | 2017-12-11 | 2021-06-24 | Senti Biosciences, Inc. | Inducible Cell Receptors for Cell-Based Therapeutics |
CN110028588A (zh) * | 2018-01-11 | 2019-07-19 | 上海细胞治疗研究院 | 抗原-Fc融合蛋白及其检测阳性CAR-T细胞的应用 |
CN112055595A (zh) | 2018-01-22 | 2020-12-08 | 恩多塞特公司 | Car t细胞的使用方法 |
US11701405B2 (en) * | 2018-01-26 | 2023-07-18 | City Of Hope | Chimeric antigen receptors and methods for reducing toxicity |
WO2019152781A1 (en) * | 2018-02-02 | 2019-08-08 | The Trustees Of The University Of Pennsylvania | Modified monocytes/macrophages/dendritic cells expressing chimeric antigen receptors and uses in diseases and disorders associated with protein aggregates |
WO2019148445A1 (en) * | 2018-02-02 | 2019-08-08 | Adagene Inc. | Precision/context-dependent activatable antibodies, and methods of making and using the same |
WO2019156795A1 (en) * | 2018-02-06 | 2019-08-15 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Fluorescein-specific cars exhibiting optimal t cell function against fl-ple labelled tumors |
CA3100327A1 (en) * | 2018-05-14 | 2019-11-21 | Harpoon Therapeutics, Inc. | Binding moiety for conditional activation of immunoglobulin molecules |
CN117089561A (zh) * | 2018-05-23 | 2023-11-21 | 上海恒润达生生物科技股份有限公司 | 靶向cd19和cd22嵌合抗原受体及其用途 |
CN109055317A (zh) * | 2018-08-07 | 2018-12-21 | 武汉大学人民医院(湖北省人民医院) | 一种AFP与HBsAg双抗原基因修饰的DC联合CIK免疫细胞及其制备方法和应用 |
CN110845621A (zh) * | 2018-08-21 | 2020-02-28 | 上海恒润达生生物科技有限公司 | 一种靶向egfr和cd19双靶点的嵌合抗原受体方法 |
CN112384231A (zh) * | 2018-08-26 | 2021-02-19 | 奥伊斯细胞生物技术公司 | 用于治疗胶质母细胞瘤的方法 |
US20220054544A1 (en) * | 2018-09-21 | 2022-02-24 | Harpoon Therapeutics, Inc. | Conditionally active receptors |
WO2020069028A1 (en) | 2018-09-25 | 2020-04-02 | Harpoon Therapeutics, Inc. | Dll3 binding proteins and methods of use |
CN110938148A (zh) * | 2018-09-25 | 2020-03-31 | 上海恒润达生生物科技有限公司 | 靶向cd19和cd22嵌合抗原受体 |
AU2019348877A1 (en) * | 2018-09-28 | 2021-05-20 | Immpact-Bio Ltd. | Methods for identifying activating antigen receptor (aCAR)/inhibitory chimeric antigen receptor (iCAR) pairs for use in cancer therapies |
JP7152080B2 (ja) * | 2018-10-19 | 2022-10-12 | カーテクセル インコーポレイテッド | 抗l1cam抗体又はその抗原結合断片、融合タンパク質、キメラ抗原受容体ポリペプチド、核酸分子、組換えベクター、効果器細胞、及び薬剤学的組成物 |
CN111100206A (zh) * | 2018-10-29 | 2020-05-05 | 上海恒润达生生物科技有限公司 | 靶向间皮素和cd19双靶点的嵌合抗原受体方法 |
CN111100205A (zh) * | 2018-10-29 | 2020-05-05 | 上海恒润达生生物科技有限公司 | 靶向新型gpc3和cd19双靶点的嵌合抗原受体方法 |
JP2022512124A (ja) | 2018-12-06 | 2022-02-02 | シートムエックス セラピューティクス,インコーポレイテッド | マトリックスメタロプロテアーゼ切断可能なおよびセリンまたはシステインプロテアーゼ切断可能な基質ならびにそれらの使用方法 |
AU2019395266A1 (en) * | 2018-12-14 | 2021-06-17 | Proviva Therapeutics (Hong Kong) Limited | IL-15 compositions and methods of use thereof |
CN111378624B (zh) * | 2018-12-29 | 2023-10-20 | 深圳市第三人民医院 | 一种靶向性抗肿瘤t细胞及其制备方法和应用 |
CA3132458A1 (en) * | 2019-03-15 | 2020-09-24 | Rutgers, The State University Of New Jersey | Cd147 chimeric antigen receptors and methods of use |
WO2020205510A1 (en) * | 2019-03-29 | 2020-10-08 | Trustees Of Boston University | Chimeric antigen receptor (car) modulation |
CN113825773B (zh) * | 2019-04-22 | 2024-02-02 | 美国杰科实验室有限公司 | 一种用于肿瘤免疫治疗的多肽组合及其制备方法 |
KR20220046008A (ko) * | 2019-05-16 | 2022-04-13 | 유니버시티 오브 워싱턴 | 새롭게 설계된 공동국지화 의존적 단백질 스위치를 사용한 초고특이적 세포 표적화 |
AU2020288499A1 (en) * | 2019-06-05 | 2022-01-27 | Chugai Seiyaku Kabushiki Kaisha | Antibody cleavage site-binding molecule |
CN114423499A (zh) * | 2019-06-06 | 2022-04-29 | 佳努克斯治疗公司 | 与肿瘤激活的t细胞衔接子相关的组合物和方法 |
WO2021030257A1 (en) * | 2019-08-14 | 2021-02-18 | The Regents Of The University Of California | Car-t cells specific for modified proteins in extracellular spaces |
JP7483896B2 (ja) * | 2020-01-17 | 2024-05-15 | エショー バイオセラピー, インク. | オフターゲット毒性を低下させるプロ抗体 |
EP4090686A4 (en) * | 2020-01-17 | 2024-03-27 | Immune Targeting Inc. | PRO-ANTIBODY REDUCING OFF-TARGET TOXICITY |
US20230092787A1 (en) * | 2020-02-17 | 2023-03-23 | University Of Virginia Patent Foundation | Car t cells targeting the integrin alphav beta3 exhibit robust anti-tumor responses against gliomas and other solid tumor malignancies |
US20230076204A1 (en) * | 2020-02-18 | 2023-03-09 | Institute For Systems Biology | Single chain trimer mhc class ii nucleic acids and proteins and methods of use |
CA3170833A1 (en) | 2020-02-21 | 2021-08-26 | Harpoon Therapeutics, Inc. | Flt3 binding proteins and methods of use |
TW202208412A (zh) * | 2020-05-06 | 2022-03-01 | 瑞士商Crispr治療公司 | 對酪胺酸蛋白激酶樣7(ptk7)特異的經掩蔽的嵌合抗原受體和表現其的免疫細胞 |
JP2023529841A (ja) | 2020-06-04 | 2023-07-12 | カリスマ セラピューティクス インコーポレイテッド | キメラ抗原受容体のための新規コンストラクト |
CN116113640A (zh) * | 2020-09-11 | 2023-05-12 | 加利福尼亚大学董事会 | 具有cd28跨膜结构域的嵌合抗原受体(car) |
JP2023547447A (ja) * | 2020-10-28 | 2023-11-10 | エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト | 改良型抗原結合受容体 |
CN118146395A (zh) * | 2021-02-08 | 2024-06-07 | 浙江大学 | 一种以内源性蛋白质分子替代单结构域抗体的嵌合抗原受体 |
EP4326754A1 (en) * | 2021-04-21 | 2024-02-28 | Cue Biopharma, Inc. | Mhc class ii t-cell modulatory polypeptides for treating type 1 diabetes mellitus (t1d) and methods of use thereof |
CN113527435B (zh) * | 2021-07-14 | 2022-06-07 | 呈诺再生医学科技(珠海横琴新区)有限公司 | 对前列腺癌细胞特异性识别的新型多肽及其衍生物与应用 |
WO2023009985A1 (en) * | 2021-07-26 | 2023-02-02 | Georgia Tech Research Corporation | Compositions and methods for in vivo protease profiling by immune cell display |
JP2024528038A (ja) | 2021-07-29 | 2024-07-26 | ソノマ バイオセラピューティクス, インコーポレイテッド | 調節性t細胞を標的として自己免疫疾患を処置するための滑膜細胞外マトリックス特異的キメラ抗原受容体 |
WO2023177851A1 (en) * | 2022-03-17 | 2023-09-21 | Singular Immune, Inc | Composition and method of use recombinant fusion protein to generate car-immune cells |
WO2023212507A1 (en) * | 2022-04-26 | 2023-11-02 | Fred Hutchinson Cancer Center | Compositions and methods for cellular immunotherapy |
CN117510615A (zh) * | 2023-01-31 | 2024-02-06 | 上海恩凯细胞技术有限公司 | SynNotch受体及其用途 |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1919931A4 (en) | 2005-08-31 | 2010-01-20 | Univ California | CELLULAR LIBRARIES OF PEPTIDE SEQUENCES (CLIPS) AND METHODS OF USE THEREOF |
MX2009010611A (es) | 2007-04-03 | 2010-03-26 | Micromet Ag | Enlazadores biespecificos, especificos para especies. |
WO2009014726A1 (en) | 2007-07-26 | 2009-01-29 | The Regents Of The University Of California | Methods for enhancing bacterial cell display of proteins and peptides |
JP6035009B2 (ja) | 2007-08-22 | 2016-11-30 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 活性化可能な結合ポリペプチドおよびその同定方法ならびに使用 |
EP2385955B1 (en) | 2009-01-12 | 2020-08-12 | CytomX Therapeutics, Inc. | Modified antibody compositions, methods of making and using thereof |
EP2768863B1 (en) | 2011-10-20 | 2017-09-27 | The U.S.A. as represented by the Secretary, Department of Health and Human Services | Anti-cd22 chimeric antigen receptors |
AU2013221672B2 (en) * | 2012-02-13 | 2017-11-09 | Seattle Children's Hospital D/B/A Seattle Children's Research Institute | Bispecific chimeric antigen receptors and therapeutic uses thereof |
IN2014MN02164A (da) * | 2012-04-27 | 2015-08-28 | Cytomx Therapeutics Inc | |
BR112015004522A2 (pt) | 2012-09-04 | 2017-11-21 | Cellectis | receptor de antígeno quimérico multicadeia e usos destes |
RU2015132436A (ru) * | 2013-01-04 | 2017-02-09 | Сайтомкс Терапьютикс, Инк. | Способы обнаружения активности протеазы в биологических системах и композиции для их осуществления |
CN103145849B (zh) | 2013-02-18 | 2014-06-11 | 冯振卿 | 嵌合抗原受体及其用途 |
DK2958943T3 (da) * | 2013-02-20 | 2019-12-09 | Univ Pennsylvania | Behandling af cancer ved anvendelse af humaniseret anti-EGFRvIII kimær antigenreceptor |
RS60759B1 (sr) | 2013-02-26 | 2020-10-30 | Memorial Sloan Kettering Cancer Center | Sastavi i postupci za imunoterapiju |
US9657105B2 (en) | 2013-03-15 | 2017-05-23 | City Of Hope | CD123-specific chimeric antigen receptor redirected T cells and methods of their use |
RU2015156888A (ru) * | 2013-06-04 | 2017-07-14 | Сайтомкс Терапьютикс, Инк. | Композиции и методы конъюгирования активируемых антител |
US20160280798A1 (en) | 2013-11-06 | 2016-09-29 | The United States Of America, As Represented By The Secretary Department Of Health & Human Service | Alk antibodies, conjugates, and chimeric antigen receptors, and their use |
US10822419B2 (en) | 2015-06-26 | 2020-11-03 | University Of Southern California | Masking chimeric antigen receptor T cells for tumor-specific activation |
-
2016
- 2016-06-27 US US15/574,743 patent/US10822419B2/en active Active
- 2016-06-27 JP JP2017567067A patent/JP2018518972A/ja active Pending
- 2016-06-27 CN CN201680037492.9A patent/CN107709356A/zh active Pending
- 2016-06-27 EP EP16815514.1A patent/EP3313874B1/en not_active Revoked
- 2016-06-27 CA CA2986604A patent/CA2986604A1/en not_active Abandoned
- 2016-06-27 WO PCT/US2016/039670 patent/WO2016210447A1/en active Application Filing
- 2016-06-27 DK DK16815514.1T patent/DK3313874T3/da active
Also Published As
Publication number | Publication date |
---|---|
US20180148508A1 (en) | 2018-05-31 |
JP2018518972A (ja) | 2018-07-19 |
US10822419B2 (en) | 2020-11-03 |
EP3313874B1 (en) | 2021-03-10 |
CN107709356A (zh) | 2018-02-16 |
WO2016210447A1 (en) | 2016-12-29 |
EP3313874A1 (en) | 2018-05-02 |
CA2986604A1 (en) | 2016-12-29 |
EP3313874A4 (en) | 2018-12-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK3313874T3 (da) | Maskering af kimære antigen-receptor t-celler til tumorspecifik aktivering | |
CL2018000281A1 (es) | Anticuerpos monoclonales contra bcma | |
CL2018000370A1 (es) | Nuevos anticuerpos anti-pd-1 | |
DK3455257T3 (da) | Anti-pd-l1-antistoffer | |
DK3332006T5 (da) | Hidtil ukendte anti-PD-L1-antistoffer | |
DK3274366T3 (da) | Kimær antigenreceptor | |
DK3043816T3 (da) | Anti-b7-h1-antistoffer til behandling af tumorer | |
DK3390441T3 (da) | Antistoffer til neutralisering af human immundefekt virus | |
DK3283110T3 (da) | Antistoffer rettet mod interleukin-36-receptor (il-36r) | |
DK2997134T3 (da) | Human anvendelse af genmanipulerede kimære antigenreceptor-(car)-t-celler | |
DK3300500T3 (da) | Triazolagonister af apj-receptoren | |
DK3447075T3 (da) | Antagonistiske antistoffer af antitumornekrosefaktorreceptor-superfamilien | |
DK3597663T3 (da) | Kimære antigenreceptorer af anti-cd70 | |
DK3126390T3 (da) | Cd33-specifikke kimære antigenreceptorer til cancerimmunterapi | |
DK3301115T3 (da) | Kontinuerlig flertrinsfremgangsmåde til oprensning af antistoffer | |
DK3539986T3 (da) | Behandling af cancer under anvendelse af humaniseret kimær anti-cd19-antigenreceptor | |
DK3556775T3 (da) | Anti-lag-3 antistoffer til behandling af hæmatologiske maligniteter | |
DK3458100T3 (da) | Selektiv reduktion af cystein-manipulerede antistoffer | |
DK3563156T3 (da) | Fremgangsmåde til separering af biomolekyler | |
DK3317394T3 (da) | Anordning til opformering af mikrovæv | |
DK3441086T3 (da) | Monoklonalt anti-PD-1-antistof | |
DK3504241T3 (da) | Anti-cd3-antistofformuleringer | |
DK3368683T3 (da) | Fremgangsmåde til kvantifikationen af pd-l1 | |
ES2977137T3 (es) | Anticuerpos anti-PD-1 | |
DK3460267T3 (da) | System til fiksering af gelænderplader |